Questcor Pharmaceuticals — FY2013 Earnings Presentation
19 slides from Questcor Pharmaceuticals's earnings presentation, Mar 3, 2014
Slide 1: Fourth Quarter and Full Year 2013 Conference Call
NASDAQ: QCOR Fourth Quarter and Full Year 2013 Conference Call
Slide 2: Conference Call Logistics
Conference Call Logistics Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 55826448
Slide 3: Safe Harbor Statement
This presentation contains forward-looking statements including, but not limited to, statements related to: our reliance on Acthar for substantially all of our net sales and profits; reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compl
Slide 4: FY-2013 Financial Highlights
28,112 vials shipped, up 36% YOY $798.9M net sales, up 57% YOY $810.4M Non-GAAP net sales, up 59% YOY FY-2013 Financial Highlights $4.76 GAAP diluted EPS, up 52% YOY $5.48 Non-GAAP diluted EPS, up 65% YOY $59.7M R&D investment, up 74% YOY Note: See Reconciliation of Non-GAAP Adjusted Financial Discl
Slide 5: Q4-2013 Financial Highlights
8,100 vials shipped, up 28% YOY $242.9M net sales, up 51% YOY $1.44 GAAP diluted EPS, up 40% YOY Q4-2013 Financial Highlights $1.67 Non-GAAP diluted EPS, up 53% YOY $19.6M R&D investment, up 62% YOY Note: See Reconciliation of Non-GAAP Adjusted Financial Disclosure slide 13.
Slide 6: New Paid Acthar Prescriptions by Therapeutic Area
Paid Rx Comparison Q4 – 2013 Q4 – 2012 Q3 – 2013 NS 390—400 _5% _5% MS 1,345—1,355 _9% _3% New Paid Acthar Prescriptions by Therapeutic Area* IS 180—185 _3% _20% Rheumatology 540—550 N/M _19% Total 2,450—2,500** _31% 0% * Includes prescriptions covered by commercial carriers, Medicare, Medicaid and
Slide 7: Expanding Acthar Sales Across Therapeutic Areas
Expanding Acthar Sales Across Therapeutic Areas Acthar Net Sales ($M) $509 $761 Multiple Sclerosis Nephrology Rheumatology Other 2009 2010 2011 2012 2013 $88 $115 $218 *Numbers on the bar graph represent actual Acthar net sales. The underlying allocation of Acthar net sales is based on Management’s
Slide 8: R&D Objective: Addressing Unmet Medical Needs with Acthar and Synacthen
R&D Objective: Addressing Unmet Medical Needs with Acthar and Synacthen Understanding the biological properties of melanocortin peptides such as Acthar and Synacthen – Specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory effects Understanding the benefit of Acth
Slide 9: Expanding the Body of Evidence for On-Label and New Indications/Targets
Pre-Clinical Phase 1 Phase 2 Phase 3 Phase 4 Expanding the Body of Evidence for On-Label and New Indications/Targets IDIOPATHIC MEMBRANOUS NEPHROPATHY SYSTEMIC LUPUS ERYTHEMATOSUS DIABETIC NEPHROPATHY AMYOTROPHIC LATERAL SCLEROSIS ACUTE RESPIRATORY DISTRESS SYNDROME
Slide 10: ALS Phase 2 Open-Label Safety Study for Acthar
ALS Phase 2 Open-Label Safety Study for Acthar Goals – Assess short-term safety and tolerability of Acthar in ALS – Inform dosage selection for future studies Study Design – Enroll up to 40 patients at multiple sites in U.S. – 8-week treatment, plus optional 28-week open label extension – Patients r
Slide 11: ARDS Phase 2 Safety and Efficacy Study for Acthar
ARDS Phase 2 Safety and Efficacy Study for Acthar Goals – Determine if Acthar increases number of ventilator-free days during 28-day treatment period – Assess if Acthar reduces mortality, organ failure, length of hospital or ICU stay – Inform dosage selection for future studies Study Design – 4-week
Slide 12: Q4-2013 Financial Results
Q4 – 2013 Q4 – 2012 Change Net Sales ($M) $242.9 $160.5 51% Fully Diluted, GAAP EPS $1.44 $1.03 40% Fully Diluted, Non-GAAP EPS $1.67 $1.09 53% Q4-2013 Financial Results Cash and Short Term Investments ($M) $320.0* $155.3 Cash Flow from Operations ($M) $105.9 $83.7 Diluted Shares Outstanding 62.3 60
Slide 13: Reconciliation of Non-GAAP Adjusted Financial Disclosure
Reconciliation of Non-GAAP Adjusted Financial Disclosure Three Months Ended December 31, Twelve Months Ended December 31, 2013 2012 2013 2012 Adjusted net income $103,697 $65,705 $336,514 $209,644 Share-based compensation expense (1) (5,358) (3,590) (19,149) (10,502) Depreciation and amortization ex
Slide 14: Notes to Reconciliation of Non-GAAP Adjusted Financial Disclosure
Notes to Reconciliation of Non-GAAP Adjusted Financial Disclosure Reconciliation of Non-GAAP Adjusted Financial Disclosure Net income per share – basic and diluted may not foot due to rounding. Use of Non-GAAP Financial Measures Our “non-GAAP adjusted net income” excludes the following items from GA
Slide 15: Q4-2013 Financial Highlights
8,100 vials shipped, up 28% YOY $242.9M net sales, up 51% YOY $1.44 GAAP diluted EPS, up 40% YOY Q4-2013 Financial Highlights $1.67 Non-GAAP diluted EPS, up 53% YOY $19.6M R&D investment, up 62% YOY Note: See Reconciliation of Non-GAAP Adjusted Financial Disclosure slide 13.
Slide 16: Annualized Quarterly Net Sales
$642 $972 Annualized Quarterly Net Sales Net Sales ($M) $117 $302 Q4 ‘10 Q4 ‘11 Q4 ‘12 Q4 ‘13 Each bar represents the applicable fourth quarter net sales multiplied by 4.
Slide 17: 3-Year Net Sales
3-Year Net Sales $160.5 $184.6 $236.3 $242.9 Quarterly Net Sales ($M) $31.3 $29.3 $36.8 $46.0 $59.8 $75.5 $96.0 $112.5 $140.3 $135.1 Q3 ‘10 Q4 ‘10 Q1 ‘11 Q2 ‘11 Q3 ‘11 Q4 ‘11 Q1 ‘12 Q2 ‘12 Q3 ‘12 Q4 ‘12 Q1 ‘13 Q2 ‘13 Q3 ‘13 Q4 ‘13
Slide 18: Strong Platform for Growth
Strong Platform for Growth Increasing penetration of current Acthar markets and expanding sales into new, approved indications – NS and MS market penetration remains modest – Rheumatology is a new Acthar market in very early development; growing rapidly – Pilot selling effort in pulmonology for symp
Slide 19: Fourth Quarter and Full Year 2013 Conference Call
NASDAQ: QCOR Fourth Quarter and Full Year 2013 Conference Call
Questcor Pharmaceuticals — FY2013 Earnings Presentation on 6ix